Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dean Goldberg

Trauma Surgery Tampa, FL Doctor of Osteopathy

NPI 1437148368 CMS profile 64495

4301 N Habana Ave, Tampa, FL 33607

Open in the dashboard

General payments

$26,799

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dean Goldberg of Tampa, FL is reported in the CMS Open Payments database as having received $26,799 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Trauma Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,319 41
2024 General $700 25
2023 General $1,603 13
2022 General $5,053 18
2021 General $5,777 10
2020 General $89 4
2019 General $259 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dean Goldberg
  • Trauma Surgery median
  • Middle half of Trauma Surgery
  • National median

In program year 2025, general payments to Dean Goldberg were reported at $13,319. Among 762 Trauma Surgery profiles paid that year, the median was $280 and the middle half received between $87 and $1,585.

Show as a table
Year Dean Goldberg Trauma Surgery median Middle half National median
2019 $259 $153 $56–$644 $163
2020 $89 $123 $39–$342 $114
2021 $5,777 $142 $45–$556 $132
2022 $5,053 $172 $59–$732 $149
2023 $1,603 $213 $83–$1,200 $160
2024 $700 $237 $86–$1,280 $164
2025 $13,319 $280 $87–$1,585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $11,908 18 payments
  2. Alexion Pharmaceuticals, Inc. $6,169 8 payments
  3. AstraZeneca Pharmaceuticals LP $4,245 11 payments
  4. TELA Bio, Inc. $1,645 10 payments
  5. PolyNovo North America LLC $987 23 payments
  6. Integra LifeSciences Corporation $648 11 payments
  7. MIMEDX Group, Inc. $177 1 payment
  8. Medtronic, Inc. $154 1 payment
  9. Davol Inc. $130 4 payments
  10. KCI USA, Inc $82 4 payments
  11. Other $654 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $10,020 7 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,715 9 payments
  3. Food and Beverage $4,175 101 payments
  4. Travel and Lodging $2,889 7 payments
Products named General payments · program years 2019–2025
  1. DAVINCI XI $10,000 6 payments
  2. Andexxa Hematology $5,714 7 payments
  3. ANDEXXA Rare Disease $4,596 11 payments
  4. Da Vinci Surgical System $1,908 12 payments
  5. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $1,576 7 payments
  6. NOVOSORB BTM $837 21 payments
  7. Integra Recon-Skin And Wound $648 11 payments
  8. Integra Recon-Skin And Wound $648 11 payments
  9. PRIMATRIX $648 11 payments
  10. Integra Recon-Skin And Wound $648 11 payments
  11. Other $2,089 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$20,974

Medicare's payments for the services billed

Medicare patients

89

Average age 77

Services billed

238

50 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 53%
Depression 48%
Chronic kidney disease 47%
Diabetes 45%
Heart failure 42%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kcentra
  • CSL Behring $35
$35 — —
XERAVA
  • La Jolla Pharmaceutical Company $34
$34 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record